Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL
Clinical trial NCT05322733 · UNKNOWN
Trial details
- NCT number
- NCT05322733
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-15
- Primary completion
- 2025-02-22
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.